REGENXBIO Stock Price, News & Analysis (NASDAQ:RGNX) $19.19 -0.31 (-1.59%) (As of 11/27/2023 ET) Add Compare Share Share Today's Range$18.63▼$19.4550-Day Range$12.89▼$20.0352-Week Range$12.82▼$25.54Volume279,638 shsAverage Volume579,697 shsMarket Capitalization$844.17 millionP/E RatioN/ADividend YieldN/APrice Target$31.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability REGENXBIO MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside62.2% Upside$31.13 Price TargetShort InterestBearish10.40% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.98) to ($2.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector268th out of 935 stocksBiological Products, Except Diagnostic Industry40th out of 161 stocks 3.3 Analyst's Opinion Consensus RatingREGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.13, REGENXBIO has a forecasted upside of 62.2% from its current price of $19.19.Amount of Analyst CoverageREGENXBIO has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.40% of the float of REGENXBIO has been sold short.Short Interest Ratio / Days to CoverREGENXBIO has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in REGENXBIO has recently decreased by 2.59%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldREGENXBIO does not currently pay a dividend.Dividend GrowthREGENXBIO does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreREGENXBIO has received a 71.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for REGENXBIO is -0.82. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for REGENXBIO this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, REGENXBIO insiders have not sold or bought any company stock.Percentage Held by Insiders13.60% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.80% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for REGENXBIO are expected to grow in the coming year, from ($4.98) to ($2.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of REGENXBIO is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of REGENXBIO is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioREGENXBIO has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About REGENXBIO Stock (NASDAQ:RGNX)REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.Read More RGNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGNX Stock News HeadlinesNovember 16, 2023 | finance.yahoo.comWall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to TradeNovember 12, 2023 | finance.yahoo.comREGENXBIO (NASDAQ:RGNX) adds US$111m to market cap in the past 7 days, though investors from five years ago are still down 72%November 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 9, 2023 | finance.yahoo.comREGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | bizjournals.comRockville biotech RegenxBio to cut workforce by 15%, pursue strategic alternatives for several programsNovember 9, 2023 | finanznachrichten.deREGENXBIO Inc.: REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial ResultsNovember 8, 2023 | marketwatch.comRegenxbio Cutting 15% of Staff, Exploring Strategic AlternativesNovember 8, 2023 | finance.yahoo.comREGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial ResultsNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 7, 2023 | benzinga.comEarnings Preview For RegenxbioNovember 3, 2023 | finance.yahoo.comREGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal DeliveryNovember 2, 2023 | msn.comRegenxbio: Biotech To Watch With 2 Possible Accelerated Approval PathwaysNovember 2, 2023 | msn.comStifel Initiates Coverage of Regenxbio (RGNX) with Buy RecommendationNovember 1, 2023 | msn.comStifel starts Regenxbio at buy; cites broad platform, deep portfolioNovember 1, 2023 | finance.yahoo.comREGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational HighlightsOctober 30, 2023 | finance.yahoo.comREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual MeetingOctober 25, 2023 | seekingalpha.comRegenxbio: Promising Yet Risky Therapeutic HorizonOctober 6, 2023 | msn.comWedbush Reiterates Regenxbio (RGNX) Neutral RecommendationOctober 5, 2023 | markets.businessinsider.comPromising DMD Gene Therapy Results Bolster Buy Rating for RegenXBio: An Analysis of Brian Skorney’s RecommendationOctober 5, 2023 | finance.yahoo.comREGENXBIO to Participate in the Jefferies CNS/Neuro SummitOctober 4, 2023 | markets.businessinsider.comHold Rating on REGENXBIO Amid Promising Yet Preliminary Duchenne Trial ResultsOctober 4, 2023 | seekingalpha.comRegenxbio up after hours on early-stage Duchenne candidateOctober 3, 2023 | seekingalpha.comOMEE, TNDM and RGNX are among after hour moversOctober 3, 2023 | finance.yahoo.comREGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle SocietySeptember 26, 2023 | finance.yahoo.comREGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle SocietySeptember 22, 2023 | finance.yahoo.comWe're Keeping An Eye On REGENXBIO's (NASDAQ:RGNX) Cash Burn RateSeptember 5, 2023 | finance.yahoo.comREGENXBIO Inc. (RGNX) Stock Historical Prices & Data - Yahoo FinanceSee More Headlines Receive RGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RGNX CUSIPN/A CIK1590877 Webwww.regenxbio.com Phone(240) 552-8181FaxN/AEmployees401Year FoundedN/APrice Target and Rating Average Stock Price Target$31.13 High Stock Price Target$55.00 Low Stock Price Target$14.00 Potential Upside/Downside+62.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($5.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-280,320,000.00 Net Margins-262.18% Pretax Margin-262.23% Return on Equity-59.54% Return on Assets-35.97% Debt Debt-to-Equity RatioN/A Current Ratio2.87 Quick Ratio2.87 Sales & Book Value Annual Sales$99.37 million Price / Sales8.50 Cash FlowN/A Price / Cash FlowN/A Book Value$11.92 per share Price / Book1.61Miscellaneous Outstanding Shares43,992,000Free Float38,009,000Market Cap$844.21 million OptionableOptionable Beta1.12 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Kenneth T. Mills (Age 48)President, CEO & Director Comp: $1.02MMr. Vittal K. Vasista (Age 55)Executive VP & CFO Comp: $671.41kMr. Curran M. Simpson M.S. (Age 61)Executive VP & COO Comp: $677.7kDr. Olivier Danos Ph.D. (Age 65)Executive VP & Chief Scientific Officer Comp: $728.06kDr. Stephen Pakola M.D. (Age 54)Executive VP & Chief Medical Officer Comp: $673.76kMr. Patrick J. Christmas II (Age 52)J.D., Executive VP & Chief Legal Officer Comp: $1.11MMs. Shiva G. FritschChief Communications & People OfficerDr. Laura A. Coruzzi J.D. (Age 69)Ph.D., Executive Vice President of Intellectual Property Dr. Ram Palanki Pharm.D. (Age 47)Executive VP of Commercial Strategy & Operations Dr. Stephen Yoo M.D. (Age 45)Consultant Comp: $573.71kMore ExecutivesKey CompetitorsScholar RockNASDAQ:SRRKValnevaNASDAQ:VALNEditas MedicineNASDAQ:EDITInhibrxNASDAQ:INBXSana BiotechnologyNASDAQ:SANAView All CompetitorsInstitutional OwnershipDeutsche Bank AGBought 2,827 shares on 11/24/2023Ownership: 0.040%Public Sector Pension Investment BoardSold 17,136 shares on 11/22/2023Ownership: 0.114%Comerica BankBought 16,104 shares on 11/21/2023Ownership: 0.037%Jacobs Levy Equity Management Inc.Bought 1,493 shares on 11/17/2023Ownership: 1.278%Tudor Investment Corp Et AlBought 9,639 shares on 11/16/2023Ownership: 0.052%View All Institutional Transactions RGNX Stock Analysis - Frequently Asked Questions Should I buy or sell REGENXBIO stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RGNX shares. View RGNX analyst ratings or view top-rated stocks. What is REGENXBIO's stock price target for 2024? 8 brokerages have issued 1 year price objectives for REGENXBIO's stock. Their RGNX share price targets range from $14.00 to $55.00. On average, they anticipate the company's stock price to reach $31.13 in the next twelve months. This suggests a possible upside of 62.2% from the stock's current price. View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts. How have RGNX shares performed in 2023? REGENXBIO's stock was trading at $22.68 on January 1st, 2023. Since then, RGNX shares have decreased by 15.4% and is now trading at $19.19. View the best growth stocks for 2023 here. When is REGENXBIO's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our RGNX earnings forecast. How were REGENXBIO's earnings last quarter? REGENXBIO Inc. (NASDAQ:RGNX) announced its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($1.41) EPS for the quarter, beating the consensus estimate of ($1.44) by $0.03. The biotechnology company had revenue of $28.90 million for the quarter, compared to the consensus estimate of $26.14 million. REGENXBIO had a negative net margin of 262.18% and a negative trailing twelve-month return on equity of 59.54%. The firm's revenue for the quarter was up 9.1% on a year-over-year basis. During the same period last year, the business posted ($1.75) earnings per share. What ETFs hold REGENXBIO's stock? ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What is Ken Mills' approval rating as REGENXBIO's CEO? 3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees. What other stocks do shareholders of REGENXBIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ). Who are REGENXBIO's major shareholders? REGENXBIO's stock is owned by a number of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (8.33%), Redmile Group LLC (5.85%), Jacobs Levy Equity Management Inc. (1.28%), Northern Trust Corp (0.98%), Bank of New York Mellon Corp (0.82%) and Charles Schwab Investment Management Inc. (0.74%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust. View institutional ownership trends. How do I buy shares of REGENXBIO? Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RGNX) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.